Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
Citi continue to see upside to Eli Lilly & Co.'s (LLY) 'already rich' valuation
November 2, 2023 11:11 AM EDTCiti analyst Andrew Baum said in a note Thursday that the Mounjaro beat for Eli Lilly & Co. (NYSE: LLY) goes on after the companys solid third-quarter results, which were boosted by the drug.
Baum reiterated a Buy rating and $675 price... More
Eli Lilly (LLY) falls after cutting full-year profit forecast
November 2, 2023 6:45 AM EDTEli Lilly (NYSE: LLY) shares fell in early Thursday trade after the company lowered its full-year outlook.
Eli Lilly now projects an EPS in the range of $6.50 to $6.70, which fell below the consensus estimate of $6.72.
"Lilly had another strong quarter in Q3... More
Eli Lilly & Co. (LLY) Tops Q3 EPS by 30c; Trims Outlook
November 2, 2023 6:31 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $0.10, $0.30 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $9.5 billion versus the consensus estimate of $8.97 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2023 EPS of $6.50-$6.70, versus the... More
